BioCryst Pharmaceuticals | BCRX - Debt


BioCryst Pharmaceuticals reported $828.6M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Chugai Pharma JPY 14.11B 1.93B Dec/2022
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
DBV Technologies USD 8.59M 295K Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 41.27M 1.14M Sep/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025